NASDAQ:CMRX

Chimerix Stock Forecast, Price & News

$6.35
+0.21 (+3.42 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.97
$6.36
50-Day Range
$5.94
$7.84
52-Week Range
$2.43
$11.57
Volume1.80 million shs
Average Volume887,517 shs
Market Capitalization$547.69 million
P/E RatioN/A
Dividend YieldN/A
Beta1.59
30 days | 90 days | 365 days | Advanced Chart
Receive CMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter.


Chimerix logo

About Chimerix

Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.20 out of 5 stars

Medical Sector

337th out of 1,350 stocks

Pharmaceutical Preparations Industry

162nd out of 664 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Chimerix (NASDAQ:CMRX) Frequently Asked Questions

Is Chimerix a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Chimerix stock.
View analyst ratings for Chimerix
or view top-rated stocks.

What stocks does MarketBeat like better than Chimerix?

Wall Street analysts have given Chimerix a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Chimerix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Chimerix's next earnings date?

Chimerix is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Chimerix
.

How were Chimerix's earnings last quarter?

Chimerix, Inc. (NASDAQ:CMRX) posted its quarterly earnings data on Thursday, August, 5th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.02. Chimerix had a negative trailing twelve-month return on equity of 54.11% and a negative net margin of 3,035.43%.
View Chimerix's earnings history
.

How has Chimerix's stock been impacted by Coronavirus (COVID-19)?

Chimerix's stock was trading at $1.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CMRX shares have increased by 341.0% and is now trading at $6.35.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CMRX?

5 equities research analysts have issued 12-month target prices for Chimerix's shares. Their forecasts range from $14.00 to $21.00. On average, they anticipate Chimerix's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 199.2% from the stock's current price.
View analysts' price targets for Chimerix
or view top-rated stocks among Wall Street analysts.

Who are Chimerix's key executives?

Chimerix's management team includes the following people:
  • Michael A. Sherman, President, Chief Executive Officer & Director
  • Michael T. Andriole, Chief Financial & Business Officer
  • Randall Lanier, Chief Scientific Officer
  • Roy W. Ware, Chief Technology & Manufacturing Officer
  • Caryn Barnett, Vice President-Clinical Operations

Who are some of Chimerix's key competitors?

What other stocks do shareholders of Chimerix own?

What is Chimerix's stock symbol?

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Who are Chimerix's major shareholders?

Chimerix's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.75%), Opaleye Management Inc. (5.37%), Vanguard Group Inc. (4.16%), State Street Corp (3.73%), Point72 Asset Management L.P. (3.69%) and Renaissance Technologies LLC (2.90%). Company insiders that own Chimerix stock include David Jakeman, Fred A Middleton, Garrett Nichols, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer.
View institutional ownership trends for Chimerix
.

Which major investors are selling Chimerix stock?

CMRX stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Goldman Sachs Group Inc., Renaissance Technologies LLC, Invesco Ltd., Acuta Capital Partners LLC, Ikarian Capital LLC, Price T Rowe Associates Inc. MD, and Russell Investments Group Ltd..
View insider buying and selling activity for Chimerix
or view top insider-selling stocks.

Which major investors are buying Chimerix stock?

CMRX stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., State Street Corp, Northern Trust Corp, Cambiar Investors LLC, Nuveen Asset Management LLC, Swiss National Bank, and Integral Health Asset Management LLC. Company insiders that have bought Chimerix stock in the last two years include Fred A Middleton, Michael A Sherman, Michael T Andriole, and Robert J Meyer.
View insider buying and selling activity for Chimerix
or or view top insider-buying stocks.

How do I buy shares of Chimerix?

Shares of CMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chimerix's stock price today?

One share of CMRX stock can currently be purchased for approximately $6.35.

How much money does Chimerix make?

Chimerix has a market capitalization of $547.69 million and generates $5.37 million in revenue each year. The biopharmaceutical company earns $-43,520,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.

How many employees does Chimerix have?

Chimerix employs 54 workers across the globe.

What is Chimerix's official website?

The official website for Chimerix is www.chimerix.com.

Where are Chimerix's headquarters?

How can I contact Chimerix?

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at (919) 806-1074 or via email at [email protected].


This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.